Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that activates three hormone receptors simultaneously: GLP-1 receptor GIP receptor Glucagon receptor This is why retatrutide is often called a triple agonist. Most currently approved obesity medications target only one or two of these pathways
During your consultation at Orange County Plastic Surgery, you will receive a thorough evaluation of your abdominal area including fat distribution, skin quality, and muscle tone
Both contain semaglutide, but Wegovy is licensed for weight management at doses up to 2.4 mg a week (and 7.2 mg a week from 2026), while Ozempic is licensed for type 2 diabetes at doses up to 2 mg a week
It primarily focuses on: Fat metabolism Lipolysis Body composition pathways Some patients combine AOD-9604 with GLP-1 therapies under medical supervision as part of comprehensive metabolic programs
US$ 20.63
US$ 22.28
US$ 23.47
US$ 25.69
US$ 25.79
